Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Christopher Benecchi Insider Profile
4 Followers
Christopher Benecchi, COO at SAGE Therapeutics, holds 44.74K shares in SAGE Therapeutics (Ticker: SAGE).
Christopher Benecchi has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Christopher Benecchi's holdings
Insider Roles
COO
Roles that Christopher Benecchi holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Christopher Benecchi
Christopher Benecchi's Trading History
List of latest transactions for each holding click on a transaction to see Christopher Benecchi's performance on stock
You May Also Like
Christopher Benecchi insider profile FAQ
What is the percentage of profitable transactions made by Christopher Benecchi?
The percentage of profitable transactions made by Christopher Benecchi is ―.
What is the average return per transaction made by Christopher Benecchi?
The average return per transaction made by Christopher Benecchi is ―.
What stocks does Christopher Benecchi hold?
Christopher Benecchi holds: SAGE stocks.
What was Christopher Benecchi’s latest transaction?
Christopher Benecchi latest transaction was an Uninformative Buy of ―.
What was Christopher Benecchi's most profitable transaction?
Christopher Benecchi’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Christopher Benecchi's role in SAGE Therapeutics?
Christopher Benecchi's role in SAGE Therapeutics is COO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.